Targeted medicine with radiation for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new targeted medicine combined with radiation for bladder cancer that has not spread into the muscle. It is for people with a specific protein on their tumor (HER2) who cannot get or benefit from standard BCG treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to join the study.
- You have had bladder cancer that has not gone into the muscle layer and you have had surgery to remove it within the past 4 weeks.
- Your tumor shows a certain protein called HER2 (score of 2+ or 3+).
- You are unable or unwilling to get BCG treatment, or BCG did not work for you.
- Your cancer is considered high or very high risk of returning.
- Your overall health is good enough to participate (no severe heart, liver, or kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) given before a second bladder surgery (re-TURBT) for people with high-risk non-muscle invasive bladder cancer that has high HER2 levels. The goal is to see if this approach improves outcomes compared to standard care.
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Hear when a new HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.